To include your compound in the COVID-19 Resource Center, submit it here.

Pacira's Exparel misses in Phase III TKA nerve block trial

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) reported top-line data from a Phase III trial in 232 patients undergoing total knee arthroplasty (TKA) showing that 133 and 266 mg Exparel bupivacaine

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE